Viatris Specialty LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy
Phase 3
Completed
- Conditions
- Acute PainPost Operative PainPain
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Viatris Specialty LLC
- Target Recruit Count
- 408
- Registration Number
- NCT06215820
- Locations
- 🇺🇸
Investigator site 105, San Antonio, Texas, United States
🇺🇸Investigator site 101, Salt Lake City, Utah, United States
🇺🇸Investigator site 112, Miami, Florida, United States
Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy
Phase 3
Completed
- Conditions
- Acute PainPost Operative PainPain
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Viatris Specialty LLC
- Target Recruit Count
- 579
- Registration Number
- NCT06215859
- Locations
- 🇺🇸
Investigator site 213, Phoenix, Arizona, United States
🇺🇸Investigator site 212, Bellaire, Texas, United States
🇺🇸Investigator site 204, Houston, Texas, United States
Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users
Phase 4
Completed
- Conditions
- Abuse Potential
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Viatris Specialty LLC
- Target Recruit Count
- 54
- Registration Number
- NCT05319756
- Locations
- 🇺🇸
Hassman Research Institute, Marlton, New Jersey, United States
Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users
Phase 4
Completed
- Conditions
- Abuse Potential
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Viatris Specialty LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05053126
- Locations
- 🇺🇸
Hassman Research Institute, Marlton, New Jersey, United States
Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience
Phase 4
Completed
- Conditions
- Abuse Potential
- Interventions
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Viatris Specialty LLC
- Target Recruit Count
- 52
- Registration Number
- NCT04570436
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc., Salt Lake City, Utah, United States
© Copyright 2025. All Rights Reserved by MedPath